Takahiro Otsuka, MD
Endocrinology, Diabetes & Metabolism · Loma Linda, CANPI 1790895803
Payments from drug & device makers
Across 595 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Abbott$1K
- Medtronic$913
- Bayer$746
- Mannkind Corporation$739
- Dexcom, Inc.$678
- plus $4K from 29 others
What the payments were for
- Travel & lodging$3764%
- Food & beverage$9,76594%
- Education$420%
- Gifts$1191%
- Other$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 117 | $1,705 |
| Abbott | 78 | $1,291 |
| Medtronic(2 entities) | 20 | $913 |
| Bayer | 38 | $746 |
| Mannkind Corporation | 45 | $739 |
| Dexcom, Inc. | 50 | $678 |
| Boehringer Ingelheim | 40 | $607 |
| Corcept Therapeutics | 28 | $521 |
| Xeris Pharmaceuticals, Inc. | 23 | $364 |
| Amgen(2 entities) | 18 | $351 |
| Sanofi-aventis U.S. LLC | 29 | $348 |
| Lilly USA, LLC | 11 | $245 |
| AstraZeneca(2 entities) | 11 | $227 |
| Ascendis Pharma Endocrinology Inc | 17 | $211 |
| Novartis | 9 | $164 |
| Insulet Corporation | 9 | $146 |
| Merck | 9 | $146 |
| Esperion Therapeutics, Inc. | 5 | $109 |
| Radius Health, Inc. | 4 | $105 |
| Lifescan, Inc. | 5 | $102 |
| Amarin Pharma, Inc. | 6 | $98 |
| Kyowa Kirin, Inc. | 4 | $95 |
| Neurocrine Biosciences, Inc. | 2 | $65 |
| Shionogi Inc | 2 | $58 |
| Amryt Pharma Holdings Ltd | 2 | $42 |
| Johnson & Johnson | 3 | $42 |
| Cequr Corporation | 1 | $39 |
| Baxter Healthcare | 1 | $38 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Ionis Pharmaceuticals, Inc. | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Smith+Nephew | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$376
How this compares
$10,341 in reported general payments places this provider in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 597 | $803,411 |
| JardianceEmpagliflozin | 285 | $272,276 |
| TrulicityDulaglutide | 130 | $198,176 |
| MounjaroTirzepatide | 142 | $168,209 |
| RybelsusSemaglutide | 36 | $65,881 |
| FarxigaDapagliflozin Propanediol | 48 | $63,177 |
| JanuviaSitagliptin Phosphate | 59 | $61,848 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 133 | $51,762 |
| AfrezzaInsulin Regular, Human | 13 | $41,092 |
| KerendiaFinerenone | 45 | $37,310 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $32,833 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $31,451 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $29,530 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 137 | $28,303 |
| Humalog Kwikpen U-100Insulin Lispro | 79 | $26,895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,705 | $869,292633 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30, Humalog Mix 75-25 | $245 | $378,868327 claims |
| Boehringer IngelheimJardiance, Glyxambi | $607 | $283,148296 claims |
| MerckJanuvia, Steglujan | $146 | $72,73874 claims |
| AstraZenecaFarxiga | $227 | $63,17748 claims |
| Mannkind CorporationAfrezza | $739 | $41,09213 claims |
| BayerKerendia | $746 | $37,31045 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $348 | $29,53022 claims |
| Johnson & JohnsonInvokana | $42 | $16,40711 claims |
| AbbVieSynthroid | $15 | $14,488161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Loma Linda
- Kevin CodornizLoma Linda$1M
- Scott LeeLoma Linda$408K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.